Matthew Campobasso Sells 1,695 Shares of Enfusion, Inc. (NYSE:ENFN) Stock

Enfusion, Inc. (NYSE:ENFN) General Counsel Matthew Campobasso sold 1,695 shares of the stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $11.38, for a total transaction of $19,289.10. Following the transaction, the general counsel now directly owns 70,946 shares in the company, valued at $807,365.48. This trade represents a 2.33 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Matthew Campobasso also recently made the following trade(s):

• On Monday, March 3rd, Matthew Campobasso sold 1,081 shares of Enfusion stock. The stock was sold at an average price of $11.48, for a total transaction of $12,409.88.
• On Tuesday, January 7th, Matthew Campobasso sold 976 shares of Enfusion stock. The stock was sold at an average price of $10.13, for a total transaction of $9,886.88.

Enfusion Price Performance

ENFN opened at $11.24 on Friday. Enfusion, Inc. has a fifty-two week low of $7.83 and a fifty-two week high of $11.80. The firm has a market capitalization of $1.44 billion, a PE ratio of 280.95, a P/E/G ratio of 1.85 and a beta of 0.95. The company’s 50-day moving average is $10.98 and its 200 day moving average is $9.89.

Enfusion (NYSE:ENFN) last posted its earnings results on Monday, March 3rd. The company reported $0.01 earnings per share for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.02). The business had revenue of $52.94 million during the quarter, compared to analyst estimates of $53.98 million. Enfusion had a return on equity of 6.67% and a net margin of 1.70%. As a group, analysts expect that Enfusion, Inc. will post 0.06 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on ENFN. Stifel Nicolaus increased their price objective on shares of Enfusion from $11.00 to $13.00 and gave the stock a “buy” rating in a research report on Wednesday, December 18th. Piper Sandler upped their target price on shares of Enfusion from $10.00 to $11.50 and gave the stock a “neutral” rating in a report on Monday, December 23rd. Finally, William Blair restated a “market perform” rating on shares of Enfusion in a report on Monday, January 13th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the stock. According to MarketBeat, Enfusion presently has a consensus rating of “Hold” and a consensus target price of $11.13.

Institutional Investors Weigh In On Enfusion

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. KLP Kapitalforvaltning AS purchased a new stake in Enfusion in the 4th quarter valued at about $75,000. Harbor Capital Advisors Inc. increased its stake in Enfusion by 12.4% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 11,887 shares of the company’s stock valued at $113,000 after buying an additional 1,315 shares during the last quarter. Millennium Management LLC purchased a new stake in Enfusion in the 4th quarter valued at about $114,000. Dark Forest Capital Management LP purchased a new stake in Enfusion in the 4th quarter valued at about $128,000. Finally, Man Group plc purchased a new stake in Enfusion in the 4th quarter valued at about $131,000. Hedge funds and other institutional investors own 81.05% of the company’s stock.

Enfusion Company Profile

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.